Mucociliary clearance in patients with chronic asthma: Effects of beta(2) agonists

Daviskas, Evangelia, Anderson, Sandra D., Shaw, Janet, Eberl, Stefan, Seale, J. Paul, Yang, Ian A. and Young, Iven H. (2005) Mucociliary clearance in patients with chronic asthma: Effects of beta(2) agonists. Respirology, 10 4: 426-435. doi:10.1111/j.1440-1843.2005.00738.x/pdf

Author Daviskas, Evangelia
Anderson, Sandra D.
Shaw, Janet
Eberl, Stefan
Seale, J. Paul
Yang, Ian A.
Young, Iven H.
Title Mucociliary clearance in patients with chronic asthma: Effects of beta(2) agonists
Formatted title
Mucociliary clearance in patients with chronic asthma: Effects of β2 agonists
Journal name Respirology   Check publisher's open access policy
ISSN 1323-7799
Publication date 2005
Sub-type Article (original research)
DOI 10.1111/j.1440-1843.2005.00738.x/pdf
Volume 10
Issue 4
Start page 426
End page 435
Total pages 10
Place of publication Richmond, VIC, Australia
Publisher Wiley-Blackwell Publishing Asia
Language eng
Abstract Chronic asthma is characterized by airway inflammation, mucus hypersecretion and impaired mucociliary clearance (MCC). We investigated baseline MCC and the acute effect of terbutaline in chronic asthmatics with sputum production while on long-term treatment with salmeterol in combination with inhaled corticosteroids (ICS). MCC was measured at baseline and in response to 1 mg terbutaline (or placebo) on three visits over 80 min in 16 asthmatics (52 +/- 13 years of age). Subjects who had greater than 10% absolute increase in MCC above baseline and placebo, after terbutaline, were categorized in group A and subjects who had less than 10% in group B. In group A subjects (n = 6), MCC increased from 23.7 +/- 4.0% at baseline to 43.7 +/- 4.9% with terbutaline (P < 0.0001) and to 34.4 +/- 5.7% with placebo (P < 0.01). In group B subjects (n = 10), MCC remained similar: 11.3 +/- 3.2% at initial baseline, 12.0 +/- 3.2% with terbutaline and 7.3 +/- 3.0% with placebo (P > 0.05). Group B subjects withdrew from all beta(2) agonists for a week and MCC was remeasured. After withdrawal, baseline MCC (7.0 +/- 1.8%) was similar to the initial baseline value (P > 0.1) and MCC with terbutaline (15.8 +/- 4.9%) was greater than baseline (P < 0.005) but remained abnormal in most subjects. Baseline percentage predicted FEV1 and FEF25-75% were 77.3 +/- 7.2 and 41.7 +/- 5.6 in group A and 59.9 +/- 8.1 and 29.5 +/- 8.4 in group B subjects, respectively. MCC was impaired in most of these asthmatics with persistent airway obstruction and sputum production, despite regular treatment with ICS and salmeterol. In addition, there was little or no stimulation of MCC acutely after terbutaline in most of these asthmatics.
Keyword Respiratory System
Beta(2)-adrenoceptor Polymorphisms
Beta(2) Agonists
Mucociliary Clearance
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 13 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 14 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 13 Aug 2007, 16:03:22 EST